TLSI Overview

New Treatment Evaluation: TriSalus Life Sciences has published clinical data on its Pressure-Enabled Drug Delivery (PEDD) technology for thyroid parenchymal embolization, showing it as a safe and effective option for patients with symptomatic thyroid disease, achieving 100% technical and clinical success in a study of 22 patients.

Future Research Initiatives: A multi-institutional registry study called PROTECT is underway to further validate these findings and explore the broader applicability of pressure-enabled embolization techniques in treating benign thyroid conditions.

TriSalus Life Sciences Exchange Offer: TriSalus Life Sciences has completed its exchange offer for Preferred Stock, allowing shareholders to convert their shares into common stock at a rate of 3.3 shares per preferred share, with approximately 98.82% of outstanding preferred shares tendered.

Amendment Approval and Future Plans: Due to sufficient shareholder agreement, the company will amend the terms of the Preferred Stock, resulting in remaining shares converting to common stock at a slightly lower rate, while continuing to focus on innovative drug delivery technologies for cancer treatment.

Exchange Offer Announcement: TriSalus Life Sciences has initiated an exchange offer for its Series A Convertible Preferred Stock, allowing shareholders to convert their preferred shares into common stock to simplify the company's capital structure and enhance transparency.

Consent Solicitation Details: The company is also seeking approval from preferred shareholders for an amendment that would enable automatic conversion of remaining preferred shares into common stock at a reduced exchange ratio, with a deadline for participation set for July 23, 2025.

New Product Launch: TriSalus Life Sciences has introduced the TriNav FLX Infusion System, enhancing trackability and flexibility for Interventional Radiologists in treating solid tumors while retaining the benefits of Pressure-Enabled Drug Delivery (PEDD).

Key Features and Impact: The system offers improved navigation through complex vascular structures with a 28% reduction in required navigation force, and it is reimbursable under specific HCPCS codes, supporting procedural planning and therapy delivery.

CFO Appointment: David Patience has been appointed as the new Chief Financial Officer of TriSalus Life Sciences, effective July 1, 2025, succeeding James E. Young who stepped down for personal reasons. Dan Giordano will serve as acting CFO during the transition.

Company Overview: TriSalus Life Sciences focuses on oncology and aims to improve treatment outcomes for patients with solid tumors through innovative drug delivery technologies and investigational immunotherapies, including their proprietary Pressure-Enabled Drug Delivery™ approach.